Kenvue Inc. (KVUE)
- Previous Close
23.39 - Open
23.44 - Bid 23.20 x 1200
- Ask 23.21 x 1100
- Day's Range
23.08 - 23.52 - 52 Week Range
17.67 - 23.55 - Volume
15,225,491 - Avg. Volume
17,371,003 - Market Cap (intraday)
44.413B - Beta (5Y Monthly) --
- PE Ratio (TTM)
40.68 - EPS (TTM)
0.57 - Earnings Date Oct 24, 2024 - Oct 28, 2024
- Forward Dividend & Yield 0.82 (3.51%)
- Ex-Dividend Date Aug 14, 2024
- 1y Target Est
22.15
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.
www.kenvue.com22,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: KVUE
View MorePerformance Overview: KVUE
Trailing total returns as of 9/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KVUE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KVUE
View MoreValuation Measures
Market Cap
44.80B
Enterprise Value
52.39B
Trailing P/E
41.04
Forward P/E
18.94
PEG Ratio (5yr expected)
6.44
Price/Sales (ttm)
2.90
Price/Book (mrq)
4.40
Enterprise Value/Revenue
3.39
Enterprise Value/EBITDA
20.61
Financial Highlights
Profitability and Income Statement
Profit Margin
7.23%
Return on Assets (ttm)
6.97%
Return on Equity (ttm)
10.55%
Revenue (ttm)
15.48B
Net Income Avi to Common (ttm)
1.12B
Diluted EPS (ttm)
0.57
Balance Sheet and Cash Flow
Total Cash (mrq)
1.01B
Total Debt/Equity (mrq)
84.56%
Levered Free Cash Flow (ttm)
1.99B